Why did the Race Oncology share price rocket 10% today?

Investors view Race Oncology’s latest release in a positive light.

| More on:
Boy in business suit smiles with arms crossed and rockets attached to his back representing the rocketing BrainChip share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Race Oncology shares surged 9.90% to finish at $1.665 on Tuesday 
  • The company released the publication of two peer review abstracts highlighting the importance of Zantrene 
  • These results supplement Race Oncology's own reported preclinical and clinical data showing Zantrene’s potential as an anti-cancer agent 

The Race Oncology Ltd (ASX: RAC) share price flew higher today following a positive announcement by the pharmaceutical company.

At Tuesday’s market close, Race Oncology shares ended the day up 9.90% to $1.665.

Let’s take a look at what the company updated the ASX with.

Race Oncology highlights peer review research poster abstracts

In its statement, Race Oncology advised that in the scientific journal, Cancer Research, two peer review abstracts have been published. This comes after a recent presentation was given at the American Association of Cancer Research (AACR) Annual Conference in April.

In the publication, both abstracts detail the new preclinical data on the anti-cancer uses of Zantrene.

The first abstract notes:

Conclusion: Through a comprehensive mechanistic analysis we explicitly demonstrate the biological and functional significance of FTO in governing PC [pancreatic cancer] tumorigenesis and maintenance of CSC; thus, targeting FTO may represent an attractive therapeutic approach for PC.

This describes preclinical data demonstrating Zantrene’s ability to inhibit FTO and suppress pancreatic carcinogenesis via targeting cancer stem cell maintenance.

FTO refers to the fat mass and obesity-associated (FTO) gene, which mostly influences the body mass index (BMI).

Pancreatic cancer is the third leading cause of cancer death and has few effective treatment options available on the market.

The second abstract states:

Conclusion: Our study establishes the functional importance of FTO in CRC [colorectal cancer] and provides novel evidence for the potential use of FTO inhibitor as an adjunctive treatment to 5FU based chemotherapy for CRC patients”.

The above paragraph explores the use of Zantrene as another treatment to be used together with the primary treatment.

This helps overcome colorectal cancer resistance to 5-FU based chemotherapy via inhibition of FTO in both cell and mouse models. Currently, resistance to 5-FU is a significant clinical issue as this drug remains a backbone of colorectal cancer treatment.

5-FU is a chemotherapy drug that is designed to slow the growth of cancer cells. This medicine is used to treat a number of cancers such as colon or rectal cancer, pancreatic cancer and more.

What did management say?

Race Oncology chief science officer, Dr Daniel Tillett commented:

This very promising research further highlights the emergence of Zantrene as an exquisitely potent inhibitor of FTO – one of the central genes in the proliferation of many cancers.

We are excited to see interest and use of Zantrene build, thanks to the efforts of great researchers like our collaborator Professor Chen and his colleagues.

Race Oncology share price review

Despite today’s strong gains, the Race Oncology share price has lost 55% over the past 12 months.

Year-to-date has fared no better, down 53% for the 6 months so far.

Based on today’s price, Race Oncology has a market capitalisation of about $241.67 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Up 50% in a month: Why all these fundies predict more greatness for the Telix Pharmaceuticals share price

Several professional fund managers say the Telix Pharmaceuticals share price is on a growth trajectory. Here's why.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Dividend Investing

Medibank shares are currently trading on a 4% dividend yield. How does this compare to NIB?

Medibank vs. NIB... who wins when it comes to dividends?

Read more »

Two healthcare workers, a male doctor in the background with a woman in scrubs in the foreground,, smile towards the camera against a plain backdrop.
Broker Notes

5 reasons to buy this ASX healthcare share: Goldman Sachs

This could be the healthcare share to buy right now...

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Up 8% in July, is there more upside in the CSL share price this earnings season?

CSL is forecast to benefit from an improved outlook for plasma collections.

Read more »

A dollar sign embedded in ice, indicating a share price freeze or trading halt
Healthcare Shares

Why is the Mesoblast share price on ice today?

Mesoblast is another share placed on pause today.

Read more »

Woman holding out her hand, symbolising a trading halt.
Healthcare Shares

Medical Developments share price halted amid ‘significant near-term opportunities’

The company seeks to raise additional capital.

Read more »

A woman stretches her arms into the sky as she rises above the crowd.
Healthcare Shares

Up 22% in a month, can the Imugene share price extend its rally?

Imugene extends its gains today.

Read more »

Doctor reading a file
Healthcare Shares

What’s been impacting the Ramsay Health share price this week?

The hospital operator has decided to go its own way...

Read more »